Diversified Trust Co Has $1.02 Million Stock Position in AtriCure, Inc. (NASDAQ:ATRC)

Diversified Trust Co raised its position in AtriCure, Inc. (NASDAQ:ATRC) by 22.5% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 33,422 shares of the medical device company’s stock after purchasing an additional 6,139 shares during the quarter. Diversified Trust Co owned approximately 0.07% of AtriCure worth $1,017,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of ATRC. Norges Bank bought a new position in AtriCure during the fourth quarter valued at approximately $9,254,000. TimesSquare Capital Management LLC raised its holdings in shares of AtriCure by 39.2% during the 3rd quarter. TimesSquare Capital Management LLC now owns 904,835 shares of the medical device company’s stock valued at $39,632,000 after purchasing an additional 254,655 shares in the last quarter. Fiera Capital Corp lifted its stake in shares of AtriCure by 28.2% in the 4th quarter. Fiera Capital Corp now owns 881,826 shares of the medical device company’s stock valued at $31,472,000 after purchasing an additional 193,769 shares during the last quarter. Wellington Management Group LLP boosted its holdings in AtriCure by 7.8% in the fourth quarter. Wellington Management Group LLP now owns 1,329,457 shares of the medical device company’s stock worth $47,448,000 after purchasing an additional 95,824 shares in the last quarter. Finally, Tudor Investment Corp Et Al acquired a new position in AtriCure during the third quarter worth $3,838,000. 99.11% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ATRC has been the subject of a number of analyst reports. Needham & Company LLC reduced their price target on AtriCure from $46.00 to $40.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. StockNews.com cut AtriCure from a “hold” rating to a “sell” rating in a research report on Wednesday, March 27th. JPMorgan Chase & Co. dropped their price target on shares of AtriCure from $42.00 to $34.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. Canaccord Genuity Group decreased their price objective on shares of AtriCure from $57.00 to $49.00 and set a “buy” rating for the company in a report on Thursday, May 2nd. Finally, Oppenheimer upgraded shares of AtriCure from a “market perform” rating to an “outperform” rating and set a $32.00 target price on the stock in a report on Tuesday, April 23rd. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $49.78.

Insider Activity at AtriCure

In other AtriCure news, insider Salvatore Privitera purchased 5,000 shares of the firm’s stock in a transaction on Thursday, May 30th. The shares were purchased at an average price of $22.25 per share, for a total transaction of $111,250.00. Following the completion of the purchase, the insider now directly owns 103,290 shares of the company’s stock, valued at $2,298,202.50. The acquisition was disclosed in a legal filing with the SEC, which is available through the SEC website. In other news, insider Justin J. Noznesky sold 1,500 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $24.09, for a total value of $36,135.00. Following the completion of the transaction, the insider now directly owns 71,284 shares of the company’s stock, valued at approximately $1,717,231.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Salvatore Privitera purchased 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $22.25 per share, for a total transaction of $111,250.00. Following the purchase, the insider now owns 103,290 shares in the company, valued at $2,298,202.50. The disclosure for this purchase can be found here. 3.20% of the stock is currently owned by corporate insiders.

AtriCure Stock Performance

NASDAQ ATRC opened at $22.50 on Tuesday. The company’s fifty day moving average is $22.35 and its two-hundred day moving average is $28.85. AtriCure, Inc. has a 52-week low of $18.94 and a 52-week high of $59.61. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.00 and a quick ratio of 2.83. The firm has a market capitalization of $1.07 billion, a price-to-earnings ratio of -28.12 and a beta of 1.44.

AtriCure (NASDAQ:ATRC) last released its earnings results on Wednesday, May 1st. The medical device company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). The firm had revenue of $108.90 million for the quarter, compared to analyst estimates of $106.86 million. AtriCure had a negative return on equity of 7.85% and a negative net margin of 8.98%. The firm’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period last year, the business earned ($0.23) earnings per share. Equities research analysts forecast that AtriCure, Inc. will post -0.75 EPS for the current year.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.